Moleculin Biotech Inc
MBRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.45M
Close$
$7.19
172.4% upside
Current Fair Value
172.4% upsideUndervalued by 172.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $17.45 Million |
|---|---|
| Enterprise Value | $7.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-28.42 |
| Beta | 1.77 |
| Outstanding Shares | 4,124,482 |
Return
| Return on Equity | -199.78% |
|---|---|
| Return on Assets | -129.83% |
| Return on Invested Capital | -48.96% |
Valuation & Multiples
| P/E Ratio | -0.12 |
|---|---|
| PEG | -0.12 |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.97 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.69
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-1.54
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.37%▼ 0.43% |
|---|---|
| Total Invested | $347,908▲ 10.39% |
| Investors Holding | 20▲ 3.00% |
ESG Score
No data
About Moleculin Biotech Inc
13 employeesMoleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs a...